Efficacy & Safety of Quetiapine Fumarate (SEROQUEL) & Placebo in the Treatment of Acutely Ill Patients With Schizophrenia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00085891|
Recruitment Status : Completed
First Posted : June 18, 2004
Last Update Posted : March 25, 2009
|Condition or disease||Intervention/treatment||Phase|
|Schizophrenia||Drug: Quetiapine Fumarate||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||535 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A 6-Week, Multicenter, Double-Blind, Double-Dummy, Randomized Comparison of the Efficacy and Safety of Sustained-Release Formulation Quetiapine Fumarate (SEROQUEL) and Placebo in the Treatment of Acutely Ill Patients With Schizophrenia|
|Study Start Date :||June 2004|
|Actual Study Completion Date :||September 2005|
- Change from baseline of the Positive and Negative Syndrome Scale (PANSS) total score at the end of treatment.
- Evaluation of secondary PANSS efficacy variables and Clinical Global Impression (CGI) variables at all study visits compared to baseline.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00085891
Show 29 Study Locations
|Study Director:||AstraZeneca Seroquel Medical Science Director, MD||AstraZeneca|